Book of Abstracts: Albany 2009

category image Albany 2009
Conversation 16
June 16-20 2009
© Adenine Press (2008)

Cisplatin Action on Content of Neutral Lipids of Rat Liver and Brain Nuclei

Cisplatin (Cis-diaminedichloroplatinum) is an effective antitumor agent commonly used in chemotherapy. Although DNA was considered primary target of cisplatin, many aspects of its action at the cellular level still remain unknown.

The plasmatic membrane constitutes the first cellular barrier that encounters cisplatin and other drugs. Many anticancer drugs show membrane effects via binding to membrane phospholipids before entering the cytoplasm. Cisplatin has been shown to decrease fatty acid synthase activity, which causes changes in cell membrane fluidity and function. Cisplatin induces apoptosis also by increase in membrane fluidity via sphingomyelinase activation.

At present a number of additional properties of cisplatin emerge including activation of signal transduction pathways leading to apoptosis. How cisplatin passed through nuclear membrane and how it penetrated into the nuclei still remains unknown. It is possible that lipids may be involved in mechanisms of cisplatin induced apoptosis as second messengers of nuclear autonomous signaling pathway, or as intranuclear structure components. It is of interest to establish to what extent cisplatin alters lipid metabolism in nuclei.

The in vivo effect of cisplatin (after 24 hour) on neutral lipids content of rat liver and brain nuclei was investigated. Neutral lipids were fractionated by microTLC technique. The quantitative valuation of fractionated neutral lipids was established by computer software FUGIFILM Science Lab. 2001 Image Gauge V 4.0. The results of our study confirm that neutral lipids of rat liver and brain nuclei exhibit diversity in content and in sensitivity to cisplatin action. These changes may be resulted from cisplatin antitumor action.

Hakobyan N.R.
Yavroyan Zh.V.
Hovhannisyan A.G.
Gevorgyan E.S.

Yerevan State Univ.
1 Alex Manoogyan
St. Yerevan, 0025

Phone: +374 10 55 67 78
Fax: +374 10 55 46 41